Detalles de la búsqueda
1.
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Jpn J Clin Oncol
; 54(4): 452-462, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271158
2.
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Cancer Immunol Immunother
; 72(8): 2829-2840, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37188764
3.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Cancer Immunol Immunother
; 72(6): 1699-1707, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36617602
4.
Enhanced immune complex formation in the lungs of patients with dermatomyositis.
Respir Res
; 24(1): 86, 2023 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36934274
5.
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer
; 23(1): 6, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36597021
6.
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
J Infect Dis
; 226(3): 431-440, 2022 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32584386
7.
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
J Gastroenterol Hepatol
; 37(2): 371-377, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34618379
8.
Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
J Gastroenterol Hepatol
; 37(1): 190-199, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34374128
9.
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Cancer Immunol Immunother
; 70(10): 2881-2892, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33751180
10.
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Invest New Drugs
; 39(1): 269-271, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32783090
11.
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
Invest New Drugs
; 39(4): 1150-1158, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33483882
12.
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.
Int J Clin Oncol
; 26(6): 1073-1082, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826027
13.
Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cancer
; 126(1): 219-227, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31503343
14.
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer
; 126(9): 1940-1948, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32022929
15.
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Liver Int
; 40(7): 1578-1589, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32304611
16.
Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis.
Hepatol Res
; 50(2): 174-181, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634412
17.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol
; 20(5): 625-635, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975627
18.
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Int J Cancer
; 144(5): 1170-1179, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30307035
19.
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Oncologist
; 24(8): 1022-1026, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023862
20.
Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
Ann Surg Oncol
; 26(6): 1916-1924, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30815801